Kailera Therapeutics Inc. (KLRA), a clinical-stage biotechnology company, on Thursday reported promising results from the Phase 1 trial for GLP-1/GIP antagonist Ribupatide, developed for treating ...

MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...

Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platformPRA-216 is a novel IL-4Rα/TSLP ...

Depending on who you ask, both the best and the worst part of working in the healthcare sector is interacting with patients.

Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume. Aardvark will host a webcast to ...

The Ibogaine Club Research Group, an independent research resource focused on ibogaine safety data and treatment center protocols, has submitted a formal public comment to the U.S. Food and Drug ...

New Report values decentralised clinical trials at $8bn in 2025, with hybrid models taking 54.1% and North America 44.2%, though data integrity and patchy regulation across regions still trouble IQVIA ...

With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced several updated poster presentations at MSToronto2026, the 10th Joint ...

Taimei Technology, a global provider of AI-powered clinical development platforms, and GreenLight Clinical (GLC), a physician-led contract research organization (CRO), today announced an expanded ...

The Negative Lists raise the thresholds that trigger data export mechanisms, easing compliance burdens and exempting certain transfers from the ...